Patient guide · Reviewed May 2026
Ozempic for Weight Loss — What It Does to Your Liver
Ozempic (semaglutide 1mg weekly) is TGA-approved in Australia for type 2 diabetes management. It is also widely used off-label for weight loss — a practice that has contributed to significant supply shortages in Australia and is now explicitly addressed in the RACGP guidance, which cautions against off-label use primarily for cosmetic weight loss in people without clinical need.
Whether you are on Ozempic for diabetes or weight management, the effects on your liver are real — and mostly positive. Here is what the evidence shows.
Published 2026-05-01 · Clinically reviewed 2026-05-31
Patient guide · Reviewed May 2026
What Ozempic Does to Liver Health — The Positive Picture
Ozempic produces weight loss in most patients — typically 10–15% of body weight over 12–18 months. Because MASLD is directly driven by obesity and metabolic…
Ozempic produces weight loss in most patients — typically 10–15% of body weight over 12–18 months. Because MASLD is directly driven by obesity and metabolic dysfunction, this weight loss produces liver benefits through three pathways:
1. Reduced liver fat. As visceral fat reduces with weight loss, the delivery of free fatty acids to the liver decreases. Liver fat content measurably reduces within 3–6 months of starting Ozempic.
2. Improved insulin sensitivity. Insulin resistance drives liver fat accumulation. As Ozempic improves insulin sensitivity, the metabolic stimulus for hepatic fat synthesis reduces.
3. Direct hepatic effects. Secondary analyses of the ESSENCE trial — which used the higher Wegovy dose — showed liver benefits that were not fully explained by weight loss alone. GLP-1 receptors on liver sinusoidal endothelial cells appear to mediate direct anti-inflammatory and anti-fibrotic effects. These mechanisms are present with semaglutide at any dose, though magnitude scales with dose.
The Weight Loss Monitoring Question
Off-label Ozempic for weight loss without a diagnosed metabolic condition creates a specific monitoring gap. Patients using Ozempic through telehealth primarily for weight loss — without type 2 diabetes — are less likely to have been assessed for MASLD, less likely to have had a FIB-4 calculation, and less likely to have a monitoring relationship with a GP who knows their metabolic history.
This matters because MASLD affects approximately 30% of Australian adults. The population seeking Ozempic for weight loss overlaps substantially with the population at risk of undiagnosed MASLD. Starting Ozempic without liver assessment means starting a medication that affects liver health without knowing your baseline.
The September 2025 MJA consensus statement is explicit: adults with obesity or two or more metabolic risk factors should be assessed for MASLD. Most people seeking Ozempic for weight management meet this criteria.
Patient guide · Reviewed May 2026
The Rapid Weight Loss Nuance
Ozempic produces weight loss that can be rapid in the first months of therapy — sometimes more than 1–1.5kg per week. This rapid fat mobilisation can…
Ozempic produces weight loss that can be rapid in the first months of therapy — sometimes more than 1–1.5kg per week. This rapid fat mobilisation can temporarily elevate liver enzymes (ALT, AST) as the liver processes the influx of released fatty acids.
This is not liver damage. It is a physiological response to rapid fat mobilisation — the same phenomenon seen with very low calorie diets and bariatric surgery. It is generally self-limiting as the rate of weight loss stabilises.
However, if you had undiagnosed MASLD before starting Ozempic, and your first blood test since starting shows elevated liver enzymes, the elevation may reflect pre-existing disease rather than drug-induced injury. Without a baseline, distinguishing these two scenarios is difficult. This is another reason baseline liver assessment matters.
When to Get a Liver Scan on Ozempic
Consider discussing liver elastography with your GP if you are on Ozempic for weight loss and:
- Have not had a FIB-4 score calculated from a blood panel
- Have had elevated liver enzymes (ALT, AST, GGT) on any blood test
- Have type 2 diabetes, metabolic syndrome, or significant central abdominal fat
- Have a family history of liver disease
- Drink alcohol regularly
A FIB-4 score from your routine blood panel is the first step — ask your GP to calculate it. If indeterminate (1.3–2.67), liver elastography is the recommended next step.
Find a liver elastography clinic near you
Search by suburb or postcode to see accredited clinics offering FibroScan and guided liver elastography across Australia.
Type a suburb or postcode and press Enter to search nearby.
Request a liver scan appointment
Submit your details and we'll route your request to the most appropriate elastography clinic in your area. Most clinics respond within 1–2 business days.
Take action
Request an appointment
Frequently asked questions
Does Ozempic for weight loss affect your liver?
Yes — positively in most cases. Ozempic produces liver fat reduction, liver enzyme improvement, and direct hepatic anti-inflammatory effects through GLP-1 receptor activation. The main monitoring concern is that patients using Ozempic off-label for weight loss are less likely to have had baseline liver assessment, making it harder to distinguish pre-existing liver disease from medication effects.
Do I need a liver scan if I am taking Ozempic for weight loss?
If you have metabolic risk factors — obesity, elevated liver enzymes, family history of liver disease — yes. A FIB-4 calculation from a blood panel is the starting point. If indeterminate, liver elastography is recommended. Many patients using Ozempic for weight loss have never had this assessment.
Is off-label Ozempic for weight loss safe for the liver?
The medication itself is safe and beneficial for liver health. The risk is not the drug — it is the monitoring gap. Off-label weight loss use is less likely to involve baseline liver assessment, monitoring blood panels, and dietitian referral than use in a properly managed clinical relationship.
Does Ozempic work as well as Wegovy for liver disease?
Ozempic at 1mg produces lower-magnitude liver benefits than Wegovy at 2.4mg, consistent with the dose difference. Ozempic produces real liver benefit — but for patients with confirmed MASH at F2–F3 requiring specific liver treatment, Wegovy at 2.4mg under the April 2026 TGA indication is the appropriate choice.
Related reading
MJA MASLD consensus September 2025; RACGP off-label Ozempic guidance; ESSENCE NEJM May 2025; AASLD Practice Guidance November 2025; TGA prescribing information semaglutide.
This article is for educational purposes only. It does not constitute medical advice. Always consult your GP or a specialist about your individual health circumstances.
Next step
Find a liver elastography clinic near you
Search participating clinics across Australia, or talk to your GP about a baseline FIB-4 and elastography.